Braver Wealth Management’s Gilead Sciences GILD Stock Holding History

Braver Wealth Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$3.15M	Sell	44,041 -20,255	-32%	-$1.51M	0.51%	60
2016 Q3	$5.09M	Buy	64,296 +24,364	+61%	+$1.98M	0.85%	31
2016 Q2	$3.33M	Sell	39,932 -27	-0.1%	-$2.4K	0.57%	48
2016 Q1	$3.67M	Sell	39,959 -4,240	-10%	-$382K	0.6%	50
2015 Q4	$4.47M	Buy	44,199 +2,868	+7%	+$298K	0.92%	28
2015 Q3	$4.06M	Buy	41,331 +17,097	+71%	+$1.9M	1.01%	25
2015 Q2	$2.84M	Buy	+24,234	New	+$2.65M	0.69%	31

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Braver Wealth Management's GILD Position: Q4 2016 in Review

Braver Wealth Management reduced its Gilead Sciences (GILD) stake by 32% in Q4 2016, selling an estimated $1.51M and leaving 44,041 shares worth $3.15M. The position accounts for 0.51% of the portfolio, ranked #60.

Braver Wealth Management first reported a position in GILD in Q2 2015 and has held it in 7 quarters since. The position peaked at $5.09M in Q3 2016. 1,572 funds tracked by Wall St. Rank hold GILD as of Q4 2016.

Braver Wealth Management held 44,041 shares of Gilead Sciences worth $3.15M as of Q4 2016.
Braver Wealth Management sold 20,255 Gilead Sciences shares in Q4 2016, an estimated $1.51M.
Gilead Sciences made up 0.51% of Braver Wealth Management's portfolio in Q4 2016, its #60 holding.
Braver Wealth Management first reported a position in Gilead Sciences in Q2 2015 and has held it in 7 quarters since.
Braver Wealth Management's Gilead Sciences position peaked at $5.09M in Q3 2016.
1,572 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2016.

Based on Braver Wealth Management's 13F filing for Q4 2016, filed 14 Feb 2017.